Kewaunee Scientific Reports Results for Second Quarter of Fiscal Year 2026

Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced results for its second quarter ended October 31, 2025. https://mma.prnewswire.com/media/338700/Kewaunee_Scientific_v1_Logo.jpg Fiscal Year 2026 Second Quarter Results: Sales during the second quarter of fiscal year 2026 were $70,096,000, an increase of 46.8% compared to sales of $47,764,000 from the prior year's second quarter. Pre-tax earnings for the quarter were […]

Credit Acceptance Honored for the 11th Time as a Best Place to Work in IT by Computerworld

(NASDAQ:CACC), Southfield, Michigan, Dec. 10, 2025 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been named one of the Best Places to Work in IT by Computerworld for the 11th year. Credit Acceptance ranked #2 among midsize companies, up six spots from last

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation – ALVO

New York, New York–(Newsfile Corp. – December 10, 2025) – WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Alvotech (NASDAQ: ALVO) resulting from allegations that Alvotech may have issued materially misleading business information to the investing public. SO WHAT: If you

Credit Acceptance Honored for the 11th Time as a Best Place to Work in IT by Computerworld

Credit Acceptance Honored for the 11th Time as a Best Place to Work in IT by Computerworld GlobeNewswire December 10, 2025 Southfield, Michigan, Dec. 10, 2025 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) has been named one of the Best Places to Work

Nuvalent Appoints Ron Squarer to Board of Directors

Nuvalent, Inc.(Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creatingpreciselytargeted therapies for clinically proven kinase targets in cancer, today announced the appointment of Ron Squarer to its Board of Directors. https://mma.prnewswire.com/media/1583941/Nuvalent_Inc_Logo_2024.jpg “We welcome Ron to our Board of Directors, where his personal dedication to advancing oncology therapeutics, demonstrated success in evolving research and development organizations

TEAMSTERS INK FIRST-EVER REGIONAL CONTRACT AT SYSCO

Over 1,000 Workers Secure 34% Wage Increase, Major Pension Gains, Protections More than 1,000 Sysco drivers and warehouse workers across Northern California and Nevada have overwhelmingly ratified the first-ever regional collective bargaining agreement negotiated by the Teamsters at Sysco. The four-year agreement delivers a 34 percent wage increase, substantial improvements to pension contributions, top-tier Teamsters

Truist decreases prime rate to 6.75%

Truist Financial Corporation (NYSE: TFC) announced a decrease in its prime lending rate to 6.75% from 7.00%, effective tomorrow, December 11, 2025. https://mma.prnewswire.com/media/1075420/TruistWhiteLogo.jpg About TruistTruist Financial Corporation is a purpose-driven financial services company committed to inspiring and building better lives and communities. Headquartered in Charlotte, North Carolina, Truist has leading market share in many of

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

(NasdaqGM:RYTM), BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host a live conference call and webcast on Thursday, December 11 at 8:00 a.m. ET to disclose preliminary data from

Corbus Pharmaceuticals to Report Results from Phase 1a Study of Oral CB1 Inverse Agonist CRB-913 for the Treatment for Obesity on Thursday, December 11, 2025

(NASDAQ:CRBP), NORWOOD, Mass., Dec. 10, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings Inc. (NASDAQ: CRBP), a clinical stage company focused on oncology and obesity, announced the Company's plan to release results of its Phase 1a single ascending dose (SAD) and multiple ascending dose (MAD) study of CRB-913 prior to the market open on Thursday, December

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome

Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome GlobeNewswire December 10, 2025 BOSTON, Dec. 10, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it will host

Scroll to Top